In a report released yesterday, Jack Allen from Robert W. Baird maintained a Buy rating on Homology Medicines (FIXX – Research Report), with a price target of $10.00. The company's shares closed last Thursday at $3.26, close to its 52-week low of $2.54. According to TipRanks.com, Allen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -15.8% and a 29.4% success rate. Allen covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Taysha Gene Therapies, and Decibel Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Homology Medicines with a $13.
https://www.tipranks.com/news/blurbs/robert-w-baird-reaffirms-their-buy-rating-on-homology-medicines-fixx?utm_source=advfn.com&utm_medium=referral
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Homology Medicines Charts.
Homology Medicines (NASDAQ:FIXX)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Homology Medicines Charts.